# AriBio Phase 3 Results for Alzheimer's Drug

> AriBio's Alzheimer's drug AR1001 nears phase 3 results with Fosun Pharmaceuticals.
- Title: AriBio Phase 3 Results for Alzheimer's Drug · Seekingalpha
- Summary: AriBio's Alzheimer's drug AR1001 nears phase 3 results with Fosun Pharmaceuticals. AriBio's AR1001 drug for Alzheimer's disease is set to show phase 3 trial…
- Keywords: aribio, fosun, alzheimers, ar1001, phase 3, alzheimers disease, phosphodiesterase-5 inhibitor, money, business, Phase, Results, Alzheimer's
- Source: Seekingalpha — https://seekingalpha.com/article/4954331-aribio-fosun-and-alzheimers-disease-close-but-perhaps-not-enough
- Author: Lane Simonian
- Published: 2026-10-15T08:11:33+00:00
- Read time: 1 min
- Topics: aribio, fosun, alzheimers, ar1001, phase 3, alzheimers disease, phosphodiesterase-5 inhibitor, money, business
## AriBio Phase 3 Trial
AriBio is set to announce phase 3 trial results for AR1001 within a month.

> AR1001 likely works better than any current drug approved for Alzheimer's disease
## Fosun Pharmaceuticals Deal
Shanghai Fosun Pharmaceuticals secured regional rights to AR1001 via a $60M option fee.
## Fosun Financials
Fosun has $5.8B in revenues and $485M in profits but high R&D costs.
## Investor Recommendation
Investor does not recommend SFOSF due to OTC status and Alzheimer's drug risks.
## Key takeaway

AriBio's AR1001 drug for Alzheimer's disease is set to show phase 3 trial results within a month, but investors are cautious due to Alzheimer's drug development risks.